Lucid Diagnostics Q1 2025 revenue $0.8M, net loss $36M; raises ~$46.7M in equity

Lucid Diagnostics Inc.

2025-Q1 EPS reported -$0.52 revenue$828,000

Revenue of $0.8M from 3,034 EsoGuard tests; GAAP net loss $36.0M ($0.52/share); adjusted loss $11.2M ($0.16/share).
Ended Q1 with $25.2M cash; subsequent public offering netted $16.1M; combined with earlier offerings total ~$46.7M raised.
Partnered with major health system for EsoGuard testing; NCI study supports expanded indication without GERD, increasing market 70%.
Cash-pay and employer channels expected to start contractually-guaranteed revenue in 2H25.
Proforma cash over $40M at Q1 end; runway extended past key Medicare and other reimbursement milestones.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.